BNP Paribas Arbitrage SA lifted its holdings in Cryolife Inc (NYSE:CRY) by 95.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,815 shares of the medical equipment provider’s stock after buying an additional 8,222 shares during the quarter. BNP Paribas Arbitrage SA owned 0.05% of Cryolife worth $382,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of CRY. Dimensional Fund Advisors LP boosted its position in shares of Cryolife by 6.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,960,221 shares of the medical equipment provider’s stock worth $39,107,000 after buying an additional 110,973 shares during the period. Vanguard Group Inc. raised its stake in Cryolife by 6.6% during the second quarter. Vanguard Group Inc. now owns 1,658,646 shares of the medical equipment provider’s stock valued at $33,090,000 after buying an additional 102,540 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of Cryolife by 18.6% during the 2nd quarter. Macquarie Group Ltd. now owns 1,387,710 shares of the medical equipment provider’s stock worth $27,685,000 after purchasing an additional 217,283 shares during the period. Northern Trust Corp raised its position in shares of Cryolife by 7.4% during the 2nd quarter. Northern Trust Corp now owns 1,171,769 shares of the medical equipment provider’s stock worth $23,377,000 after purchasing an additional 81,090 shares during the period. Finally, State Street Corp raised its position in shares of Cryolife by 5.2% during the 2nd quarter. State Street Corp now owns 758,840 shares of the medical equipment provider’s stock worth $15,143,000 after purchasing an additional 37,279 shares during the period. Institutional investors own 73.28% of the company’s stock.
Several analysts recently commented on the company. Zacks Investment Research cut Cryolife from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Lake Street Capital raised their price objective on Cryolife to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Northland Securities reaffirmed a “buy” rating and issued a $23.50 target price on shares of Cryolife in a research report on Monday, November 13th. TheStreet lowered Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Finally, Canaccord Genuity restated a “buy” rating and set a $25.00 target price on shares of Cryolife in a report on Monday, October 9th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Cryolife currently has a consensus rating of “Hold” and an average price target of $23.63.
In other Cryolife news, CAO Amy Horton sold 4,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total value of $76,000.00. Following the transaction, the chief accounting officer now directly owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP David C. Gale sold 20,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $19.63, for a total transaction of $392,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,190 shares of company stock valued at $1,138,240. Company insiders own 6.00% of the company’s stock.
Cryolife Inc (NYSE:CRY) traded down $0.05 during mid-day trading on Tuesday, reaching $19.10. 211,624 shares of the company traded hands, compared to its average volume of 194,000. The company has a market cap of $640.71, a PE ratio of 68.21 and a beta of 0.82. Cryolife Inc has a 1 year low of $14.02 and a 1 year high of $24.00. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29.
Cryolife (NYSE:CRY) last announced its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. The company had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. Cryolife had a net margin of 5.28% and a return on equity of 6.43%. The firm’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.13 EPS. equities research analysts anticipate that Cryolife Inc will post 0.28 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “BNP Paribas Arbitrage SA Has $382,000 Position in Cryolife Inc (NYSE:CRY)” was originally reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.truebluetribune.com/2018/01/03/bnp-paribas-arbitrage-sa-raises-stake-in-cryolife-inc-cry.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.